FRANKLIN STREET ADVISORS INC /NC - PUMA BIOTECHNOLOGY INC ownership

PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 160 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2017. The put-call ratio across all filers is 1.25 and the average weighting 0.2%.

Quarter-by-quarter ownership
FRANKLIN STREET ADVISORS INC /NC ownership history of PUMA BIOTECHNOLOGY INC
ValueSharesWeighting
Q3 2018$459,000
-61.2%
10,000
-50.0%
0.06%
-64.2%
Q2 2018$1,183,000
-21.0%
20,000
-9.1%
0.17%
-22.8%
Q1 2018$1,497,000
-31.2%
22,0000.0%0.22%
-31.1%
Q4 2017$2,175,000
-17.5%
22,0000.0%0.32%
-24.8%
Q3 2017$2,635,000
+31.1%
22,000
-4.3%
0.43%
+25.6%
Q2 2017$2,010,000
+80.1%
23,000
-23.3%
0.34%
+74.6%
Q1 2017$1,116,000
+25.4%
30,000
+3.4%
0.20%
+25.5%
Q4 2016$890,000
-55.3%
29,000
-2.4%
0.16%
-56.6%
Q3 2016$1,991,000
+96.4%
29,700
-12.7%
0.36%
+88.5%
Q2 2016$1,014,000
+4.4%
34,025
+3.0%
0.19%0.0%
Q1 2016$971,000
-16.0%
33,045
+124.1%
0.19%
-15.4%
Q4 2015$1,156,000
+6.5%
14,745
+2.4%
0.23%
+5.6%
Q3 2015$1,085,000
-25.9%
14,395
+14.7%
0.22%
-17.9%
Q2 2015$1,465,000
-35.5%
12,550
+30.5%
0.26%
-37.0%
Q1 2015$2,271,000
-39.3%
9,620
-51.3%
0.42%
-41.6%
Q4 2014$3,739,000
-28.7%
19,755
-10.2%
0.71%
-28.6%
Q3 2014$5,246,000
+246.0%
21,990
-4.3%
1.00%
+243.8%
Q2 2014$1,516,000
-34.4%
22,975
+3.5%
0.29%
-37.4%
Q1 2014$2,312,000
-21.2%
22,200
-21.7%
0.46%
-21.9%
Q4 2013$2,935,000
+92.2%
28,350
-0.4%
0.59%
+72.9%
Q3 2013$1,527,000
+11.2%
28,450
-8.1%
0.34%
+1.8%
Q2 2013$1,373,00030,9500.34%
Other shareholders
PUMA BIOTECHNOLOGY INC shareholders Q2 2017
NameSharesValueWeighting ↓
Sarissa Capital Management LP 1,417,000$18,010,0002.24%
Palo Alto Investors LP 1,405,680$17,866,0000.87%
PFM Health Sciences, LP 2,838,376$36,076,0000.68%
TANG CAPITAL MANAGEMENT LLC 349,400$4,441,0000.60%
Capital Impact Advisors, LLC 127,029$1,615,0000.59%
Leap Investments LP 29,100$370,0000.50%
Spark Investment Management LLC 454,300$5,774,0000.40%
Partner Investment Management, L.P. 27,567$350,0000.37%
BOGLE INVESTMENT MANAGEMENT L P /DE/ 262,945$3,342,0000.26%
Rock Springs Capital Management LP 534,400$6,792,0000.25%
View complete list of PUMA BIOTECHNOLOGY INC shareholders